Arca
Skip to content
Tools
Tools

Relapsed or refractory acute myeloid leukemia (AML)

Drug research and approvals for relapsed or refractory acute myeloid leukemia (AML): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 96 studies of relapsed or refractory acute myeloid leukemia (AML) are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, FDA has 14 approved and 23 open orphan designations naming it, and the EU has 7 authorised medicines for it.

  • Recruiting worldwide: 96
  • Trials authorized in Canada: 19
  • FDA orphan approvals: 14
  • EU medicines: 7

Recruiting now

Newest posted first, of 96 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 19; search them all in Canada trials
Sep 25, 2026A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…Vicrimenib (S243249, BN104)ServierPending
May 27, 2026A phase 1b study of the safety and pharmacokinetics of pivekimab sunirine in pediatric subjects with relapsed or refractory acute myeloid leukemia (AML)Pivekimab sunirine (IMGN-632)AbbViePending
May 26, 2026A phase 2 trial of gilteritinib in combination with azacitidine and venetoclax to overcome venetoclax resistance in patients with relapsed/refractory FLT3-wild…GilteritinibBC Cancer, Part of The Provincial Health Services AuthorityPending
Mar 20, 2024Phase I multicenter, open-label, first-in-human study of BMS-986497 (ORM-6151) in subjects with relapsed or refractory acute myeloid leukemia or…BMS-986497 (ORM-6151)Bristol-Myers SquibbClosed
Mar 25, 2022Managed access program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification…KymriahNovartis PharmaceuticalsPending
Jul 8, 2021A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine versus physician's choice of…MagrolimabGilead SciencesClosed
Jun 18, 2021A phase 1b dose escalation study of lemzoparlimab (TJ011133) in combination with azacitidine and/or venetoclax in subjects with acute myeloid leukemia (AML) or…Lemzoparlimab/ Venetoclax/ AzacitidineAbbViePending
May 6, 2020An open-label feasibility study to assess the safety and pharmacokinetics of enasidenib in pediatric patients with relapsed/refractory acute myeloid leukemia…EnasidenibChildrens Oncology GroupOngoing
Oct 11, 2019A phase 1/2, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of quizartinib administered in…QuizartinibDaiichi SankyoOngoing
Sep 20, 2019A phase I/II, multicenter, open-label, multi-arm study evaluating the safety, tolerability, pharmacokinetics, and preliminary activity of idasanutlin in…Idasanutlin (RO5503781) / Venetoclax (RO5537382) / Cytarabine / Topotecan /…RocheClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 37
May 13, 2026InqoviIn combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have…Taiho Oncology Inc.Approved
Nov 13, 2025KomziftiTreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who…Kura Oncology, Inc.Approved
Oct 24, 2025RevuforjTreatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric…Syndax Pharmaceuticals, Inc.Approved
Dec 1, 2022RezlidhiaTreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)…Rigel Pharmaceuticals, Inc.Approved
May 25, 2022TibsovoIn combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible…Servier Pharmaceuticals LLCApproved
Mar 30, 2021VYXEOS ; Vyxeos ; VyxeosTreatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults…Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)Approved
May 2, 2019TibsovoTIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)…Servier Pharmaceuticals LLCApproved
Nov 28, 2018XospataXOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like…Astellas Pharma US, Inc.Approved
Nov 21, 2018DaurismoDAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult…Pfizer, Inc.Approved
Nov 21, 2018VenclextaVENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute…AbbVie Inc.Approved
Jul 20, 2018TibsovoTIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible…Servier Pharmaceuticals LLCApproved
Aug 3, 2017VYXEOS ; Vyxeos ; VyxeosTreatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)Approved
Aug 1, 2017IdhifaTreatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as…Celgene CorporationApproved
Apr 28, 2017RydaptTreatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved…Novartis Pharmaceuticals CorporationApproved
Apr 24, 2024Selective small molecule messenger RNA (mRNA) degrader of…Treatment of acute myeloid leukemia (AML)Remix TherapeuticsDesignated

Medicines authorised in the EU

Newest first
Sep 15, 2023InaqoviCedazuridine; decitabineOtsuka Pharmaceutical Netherlands B.V.EMA ↗
May 4, 2023TibsovoIvosidenib · orphanLes Laboratoires ServierEMA ↗
Jun 17, 2021OnuregAzacitidineBristol-Myers Squibb Pharma EEIGEMA ↗
Jun 26, 2020DaurismoGlasdegib · orphanPfizer Europe MA EEIGEMA ↗
Oct 24, 2019XospataGilteritinib · orphanAstellas Pharma Europe B.V.EMA ↗
Aug 23, 2018Vyxeos liposomal (previously Vyxeos)Daunorubicin; cytarabine · orphanJazz Pharmaceuticals Ireland LimitedEMA ↗
Sep 20, 2012DacogenDecitabineEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.